XML 27 R17.htm IDEA: XBRL DOCUMENT
v3.23.1

STOCK-BASED COMPENSATION | 3 Months Ended
--- | ---
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract] |
STOCK-BASED COMPENSATION | 11. STOCK-BASED COMPENSATION The following table summarizes the Company’s stock awards granted for each of the periods indicated:
|  | For the Three Months Ended March 31, |  |
|  | 2023 |  |  | 2022 |  |
|  | Grants |  |  | Weighted Average Grant Date Fair Value |  |  | Grants |  |  | Weighted Average Grant Date Fair Value |  |
Stock options |  |  | 1,030,349 |  |  | $ | 72.80 |  |  |  | 1,291,537 |  |  | $ | 46.99 |  |
Restricted stock units* |  |  | 1,075,911 |  |  | $ | 154.91 |  |  |  | 712,435 |  |  | $ | 79.98 |  |
*Included in restricted stock units (“RSUs”) for the three months ended March 31, 2023 and 2022 are 502,225 and 38,500 shares, respectively, with performance conditions which are related to regulatory approval of certain of the Company's product candidates. As of March 31, 2023, none of the performance conditions are probable of being achieved. If the performance milestones are achieved within the required time frame, the Company may recognize up to $78.3 million of stock-based compensation related to these grants. Stock options and the remaining RSUs granted during the periods presented in the table have only service-based criteria and vest over four years. Grant Modification In June 2017, the Company granted its Chief Executive Officer 3,300,000 options with service and market conditions which were subject to a five-year cliff vesting schedule. On April 19, 2022 (the “Effective Date”), the Company entered into an agreement with its Chief Executive Officer to modify the vesting conditions of the options. Under the agreement, one-third of the options vested (the “Vested Tranche”) on the Effective Date with no required service or market conditions. Subject to the Chief Executive Officer's continued service through each applicable vesting date and the compound annual growth rate of the Company's common stock exceeding that of the Nasdaq Biotech Index in varying percentages, the remaining two-thirds of the options (the “Unvested Tranche”) shall vest in varying increments at any time between the Effective Date and June 26, 2025 (the “Measurement Period”) when (and if) the average of the closing price of the Company’s common stock during any consecutive 20 trading day period during the Measurement Period reaches certain pre-determined target stock prices. The Unvested Tranche represents awards with market conditions only. Both the pre- and post-modification fair values for the Unvested Tranche are determined by a lattice model with Monte Carlo simulations. The incremental compensation costs related to varying increments of the Unvested Tranche will be recognized as stock-based compensation expense over their respective derived service periods, an output from the Monte Carlo simulation, and will be fully recognized over a 1.3 year period from the Effective Date. During the three months ended March 31, 2023, 550,110 optio ns relating to the Unvested Tranche met the conditions for vesting as the average closing price of the Company's common stock exceeded $128.65 during 20 consecutive trading days in March 2023 and the compound annual growth rate of the Company's common stock exceeded that of the Nasdaq Biotech Index by greater than 5%. For the three months ended March 31, 2023, the Company recorded $8.4 million of stock-based compensation expense in total related to the Chief Executive Officer's awards. As of March 31, 2023, the Company is expected to recognize incremental compensation cost of $5.0 million over approximately the next four months a ssociated with the Unvested Tranche. Stock-based Compensation Expense For the three months ended March 31, 2023 and 2022, total stock-based compensation expense was $41.3 million and $29.2 million, respectively. The following table summarizes stock-based compensation expense by function included within the unaudited condensed consolidated statements of operations and comprehensive loss:
|  | For the Three Months Ended March 31, |
|  | 2023 |  |  | 2022 |
| (in thousands) |
Research and development |  | $ | 16,413 |  |  | $ | 13,068 |
Selling, general and administrative |  |  | 24,837 |  |  |  | 16,130 |
Total stock-based compensation expense |  | $ | 41,250 |  |  | $ | 29,198 |
The following table summarizes stock-based compensation expense by grant type included within the unaudited condensed consolidated statements of operations and comprehensive loss:
|  | For the Three Months Ended March 31, |
|  | 2023 |  |  | 2022 |
| (in thousands) |
Stock options |  | $ | 23,830 |  |  | $ | 16,406 |
Restricted stock units |  |  | 16,140 |  |  |  | 11,365 |
Employee stock purchase plan |  |  | 1,280 |  |  |  | 1,427 |
Total stock-based compensation expense |  | $ | 41,250 |  |  | $ | 29,198 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI https://asc.fasb.org/topic&trid=2228938 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (l) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(2) -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration